Tags : Moleculin

Weekly Snapshot

PharmaShots Weekly Snapshot (March 16-20, 2020)

1. Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform Published: Mar 19, 2020 | Tags: Merck, Collaborates, Dragonfly, Develop, Commercialize, Novel Therapies, Utilizing, TriNKET Platform 2.  BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US Published: Mar 20, 2020 | Tags: BGI, Reports, Availability, RT-PCR, SARS-CoV-2 […]Read More

COVID-19 Pharma

Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses

Shots: Moleculin will provide its lead candidate, WP1122, and related inhibitors along with technical support while UTMB will investigate candidates against multiple viruses including COVID-19, in connection with UTMB’s CBEID UTMB’s CBEID collaborates with the Galveston National Laboratory, which is funded by NIAID the US Department of Defense, the US Centers for Disease Control & […]Read More

Pharma

Moleculin Signs a Clinical Research Agreement with Emory University for

Shots: Moleculin collaborated with Emory University to conduct P-I trial for WP1066 to treat recurrent or refractory malignant brain tumors in pediatric patients The trial will be conducted at Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, with its expected recruitment in H2’19 WP1066 is an immuno-stimulating STAT3 inhibitor will be evaluated […]Read More

Pharma

Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in

Shots: The P-I trial is assessing WP1066 in 15 patients with relapsed brain tumor for 6 to 8mos, testing its safety and tolerability in patients at MD Anderson Cancer Centre WP1066 a novel STAT3i (originated from active ingredient in propolis) has shown promising results in animal studies inhibiting tumor growth with improvement in survival Mayo […]Read More